In the first funding cycle (2001-2006), the MMC-VICC Cancer Partnership primarily focused on basic and clinical cancer research, with only one clinic-based behavioral research project, and the Partnership lacked a community outreach component. In 2006, the Partnership created a new Community Outreach Core (COC) guided by a framework of community-based participatory research (CBPR) to further the aims of the Cancer Partnership In reducing cancer disparities. Given its strong history of community-based research with minority communities, TSU was brought in as a subcontractor to co-lead the new COC, under the leadership of Dr. Baqar Husaini (TSU), Dr. Elizabeth Williams (VICC) and Dr. Paul Juarez (MMC) and with Dr. Pamela Hull (TSU). In August 2010, Dr. Wujcik took over as VICC Co-Leader when Dr. Williams left VICC to join the TSU public health faculty.
|Brown, Shyretha; Whalen, Margaret (2015) Tributyltin alters secretion of interleukin 1 beta from human immune cells. J Appl Toxicol 35:895-908|
|Vaiopoulou, Anna; Gazouli, Maria; Papadopoulou, Aggeliki et al. (2015) Serum protein profiling of adults and children with Crohn disease. J Pediatr Gastroenterol Nutr 60:42-7|
|Cui, Yong; Deming-Halverson, Sandra L; Beeghly-Fadiel, Alicia et al. (2014) Interactions of hormone replacement therapy, body weight, and bilateral oophorectomy in breast cancer risk. Clin Cancer Res 20:1169-78|
|Hull, Pamela C; Williams, Elizabeth A; Khabele, Dineo et al. (2014) HPV vaccine use among African American girls: qualitative formative research using a participatory social marketing approach. Gynecol Oncol 132 Suppl 1:S13-20|
|Patel, Kushal; Kanu, Mohamed; Liu, Jianguo et al. (2014) Factors influencing breast cancer screening in low-income African Americans in Tennessee. J Community Health 39:943-50|
|Rekhadevi, P V; Diggs, D L; Huderson, A C et al. (2014) Metabolism of the environmental toxicant benzo(a)pyrene by subcellular fractions of human ovary. Hum Exp Toxicol 33:196-202|
|Xie, Yingqiu; Liu, Shenji; Lu, Wenfu et al. (2014) Slug regulates E-cadherin repression via p19Arf in prostate tumorigenesis. Mol Oncol 8:1355-64|